Li Bo, Zhang Li-hua, Yang Xin-guo, Liu Xiong-tao, Ren Yin-gang
Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, 1 Xinsi Road, Xian, Shanxi, P.R China.
Clin Invest Med. 2010 Dec 1;33(6):E398-404. doi: 10.25011/cim.v33i6.14591.
Patients with metabolic syndrome are at high-risk for development of atherosclerosis and cardiovascular events. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1(sLOX-1) is associated with coronary artery disease (CAD) and metabolic disorders. We sought to assess whether serum sLOX-1 levels are correlated with the presence and severity of CAD in patients with metabolic syndrome (MetS) undergoing coronary angiography.
Serum sLOX-1 levels were measured in 112 consecutive patients with MetS, undergoing coronary angiography for the evaluation of CAD. The severity of CAD was assessed by angiographic Gensini score system.
Serum sLOX-1 levels were significantly higher in MetS patients with CAD (n=69) than in those without CAD (n=43) (0.925 [range 0.137 to 1.432] ng/ml vs. 0.207 [range 0.063 to 0.774] ng/ml, P < 0.01). Multivariate logistic regression analysis revealed that serum sLOX-1 level was independently associated with the presence of CAD (odds ratio 2.489, 95% confidence interval 1.290-4.802; P < 0.01). Serum sLOX-1 levels were positively correlated with the Gensini score (ρ: 0.394, P < 0.01) after adjusting for other clinical characteristics.
High sLOX-1 levels are associated with the presence and severity of CAD in patients with MetS. The measurement of serum sLOX-1may be potentially useful in predicting the presence and severity of CAD in patients with MetS.
代谢综合征患者发生动脉粥样硬化和心血管事件的风险较高。血清可溶性凝集素样氧化型低密度脂蛋白受体-1（sLOX-1）与冠状动脉疾病（CAD）及代谢紊乱相关。我们旨在评估接受冠状动脉造影的代谢综合征（MetS）患者血清sLOX-1水平是否与CAD的存在及严重程度相关。
对112例连续接受冠状动脉造影以评估CAD的MetS患者测定血清sLOX-1水平。采用血管造影Gensini评分系统评估CAD的严重程度。
患有CAD的MetS患者（n = 69）血清sLOX-1水平显著高于无CAD的患者（n = 43）（0.925[范围0.137至1.432]ng/ml对0.207[范围0.063至0.774]ng/ml，P < 0.01）。多因素逻辑回归分析显示血清sLOX-1水平与CAD的存在独立相关（比值比2.489，95%置信区间1.290 - 4.802；P < 0.01）。在调整其他临床特征后，血清sLOX-1水平与Gensini评分呈正相关（ρ：0.394，P < 0.01）。
高sLOX-1水平与MetS患者CAD的存在及严重程度相关。测定血清sLOX-1可能有助于预测MetS患者CAD的存在及严重程度。
